ROME--(BUSINESS WIRE)-- SOOFT italia S.p.A., a company of OOgroup, announce the worldwide launch of its “Device and method for Corneal delivery of Riboflavin by Iontophoresis procedure for the treatment of keratoconus®“, in the field of corneal collagen cross linking. The entire procedure has obtained the CE mark certification.
Commonly the cross linking is used to treat degenerative keratoconus, post- lasik ectasia and ocular infections. In most of these cases the actual procedures required to remove the corneal epithelium in order to allow riboflavin to penetrate in the cornea, with well-known side effects and patients discomfort.
The use of corneal Iontophoresis technology, Iontofor CXL®, allows the riboflavin to penetrate in the cornea with epi-on in only 5 minutes, with clear advantages for the ophthalmogists and the patients.
For a more complete use of the Iontophoresis procedure SOOFT italia S.p.A. has developed a new riboflavin solution, Ricrolin+® and a new Power Generator I-ON CXL®.
“SOOFT italia S.p.A. is pleased to announce the CE mark certification for its “Device and Methods for Corneal Delivery of Riboflavin by Iontophoresis“ (IontoforCXL®, Ricrolin+®, I-ONCX®L).
This achievement has allowed SOOFT italia S.p.A. to serve its customers and patients in most countries in the world, with clear advantages for both the ophthalmogists and patients. “Iontophoresis is an excellent delivery system, which allowed to perform the entire cross linking procedure in about 10-15 minutes, instead than 1 hour as for the actual procedures in the market“ said Mr. Fulvio Foschini Executive Vice President OOgroup.
He continued “this new technology will add to our current patent portfolio, allowing SOOFT italia S.p.A. to reinforce its worldwide leadership in the field of Corneal Collagen Cross Linking .
About SOOFT italia S.p.A. a Company of OOgroup.
SOOFT italia S.p.A. a Company of OOgroup , is an Italian pharmaceutical firm specialized in the research of new solutions , in carrying out and marketing of products for general and specific eyes health.
SOOFT italia S.p.A. is mainly involved in the most common ocular pathologies, ranging from anterior segment (dry eye, ocular inflammations, periocular hygiene) to severe retinal pathologies (Age Related Macular Degeneration) and Corneal Collagen Cross-Linking.
SOOFT italia S.p.A. is present in more than 25 countries, sharing its technology with the KOLs and Partners around the world. Its innovation is mainly used to improve the quality of life by protecting the quality of sight.
Brand Manager International Department
mob.: +39 3466829205